Able Laboratories Extends Bond Tender Offer.Business Editors SOUTH PLAINFIELD, N.J.--(BUSINESS WIRE)--May 1, 2003 Able Laboratories, Inc. (Nasdaq NMS See NetWare Management System. : ABRX, BSE See Bombay Stock Exchange. BSE See Boston Stock Exchange (BSE). : AAB), today announced that it is extending the term of its offer to purchase the New Jersey Economic Development Authority The New Jersey Economic Development Authority (EDA) is an independent, quasi-governmental self-supporting entity in the U.S. state of New Jersey dedicated to broadening and expanding the state's economic base. Industrial Development Revenue Bonds, Series 1999A (Able Laboratories, Inc. Project) CUSIP CUSIP See: Committee on Uniform Securities Identification Procedures CUSIP See Committee on Uniform Securities Identification Procedures. No. 64577LAN (Local Area Network) A communications network that serves users within a confined geographical area. The "clients" are the user's workstations typically running Windows, although Mac and Linux clients are also used. 2. The new expiration date is Friday, May 9, 2003 at 5:00 PM EDT extended from the original expiration date of Wednesday, April 30, 2003 at 5:00 PM EDT. In addition, the settlement date of the tender has been extended from Friday, May 2, 2003 to Friday, May 16, 2003. The Company is extending the term of its offer to provide an opportunity for any additional bondholders who may wish to tender their bonds to do so on or before the new expiration date. Able Laboratories is a developer and manufacturer of generic pharmaceuticals. Further information on Able may be found on the Company's web site, www.ablelabs.com. Except for historical facts, the statements in this news release, as well as oral statements or other written statements made or to be made by Able Laboratories, Inc., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 and involve risks and uncertainties. For example, statements concerning the Company's capital resources, including its offer to purchase the Series 1999A Bonds and related activities, are forward-looking statements. Forward-looking statements are merely the Company's current predictions of future events. The statements are inherently uncertain, and actual results could differ materially from the statements made herein. There is no assurance that the Company will continue to achieve the sales levels necessary to make its operations profitable or that ANDA ANDA abbr. abbreviated new drug application filings and approvals will be completed and obtained as anticipated. For a description of additional risks, and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2002. The Company assumes no obligation to update its forward-looking statements to reflect new information and developments. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion